Features of the systemic influence of cervical cancer on peripheral blood and hemostasis according to the tumor histological subtype

Aim. To identify the features of the systemic effect on hematopoiesis and the blood coagulation system of different histological subtypes of cervical cancer (CC).
Materials and methods. A single-center retrospective cohort study of 428 patients (61 patients with high grade squamous intraepithelial lesion (carcinoma in situ) and 367 patients with CC) examined from 1997 to 2022 in the Polyclinic of P. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia. The age of patients was from 18 to 90 years (median age – 42 [34; 51] years). Patients were divided into 4 groups: group 1 – patients with high grade squamous intraepithelial lesion and 3 groups depending on tumor’s histological subtype (squamous cell, glandular squamous cell, adenocarcinoma). Demographic and clinical data were analyzed including laboratory tests (general blood count, biochemical blood test and iron metabolism and coagulograms (total 32 variables)) compared to clinical and surgical stages of CC.
Results. High grade squamous intraepithelial lesion does not have a systemic effect on the parameters of general, biochemical blood tests and hemostasis (p >0.05). On the other hand, statistically significant changes were found in the parameters of routine laboratory blood tests, which correlate with the results of microinvasive analysis of CC, thus revealing the systemic effect of a malignant tumor: at p ≤0.001 for thrombin time, total protein, alkaline phosphatase levels; at p ≤0.05 for alanine aminotransferase, aspartate aminotransferase, C-reactive protein, serum iron and urea levels. Among patients with CC, statistically significant (p<0.001) correlations were obtained between hematological, hemostasiological and biochemical blood parameters. Of statistical significance, the presence of the glandular component in the tumor increases the systemic effect of CC on blood parameters, hemostasis, markers of inflammation and iron metabolism: leukocytosis and maximum erythrocyte sedimentation rate values compared to CC, high fibrinogen and the level of soluble fibrin-monomer complexes which increased activation of coagulation hemostasis along the common coagulation pathway (thrombin time) (p<0.001). It leads to an increase in the risk of venous thromboembolic complications in this category of patients.
Conclusion. The identified changes in blood parameters made it possible to reveal the unique biological characteristics of each histological subtype of CC, including biochemical ones, which will help in developing an improved diagnosis of CC depending on the histological subtype and stage of the disease, along with developing preventive measures and treatment methods adapted to each specific case.

1. Cancer Today – Global Cancer Observatory. Available at: https://gco.iarc.fr/today/online-analysistable?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=2&statistic=5&prevalence=1&population_g.

2. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: P. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia, 2022. 252 p. (In Russ.)

3. Birgegard G., Aapro M.S., Bokemeyer C. et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(Suppl 1):3–11. DOI: 10.1159/000083128

4. Stuklov N.I., Levakov S.A., Banke N.S., Strazhev S.V. Features of anemia in diseases of the female reproductive system, recommendations for treatment. Farmateka = Pharmateca 2010;17(211):109–14. (In Russ.)

5. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6(6):401–10.

6. Sermsathanasawadi N., Thangrod R., Hongku K. et al. Prevalence of perioperative asymptomatic proximal deep vein thrombosis in Thai gynecologic cancer patients. J Med Assoc Thai 2014;97(2):153–8.

7. Ludwig R.J., Alban S., Bistrian R. et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006;95(3):535–40. DOI: 10.1160/TH05-07-0515

8. Sideras K., Schaefer P.L., Okuno S.H. et al. Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial. Mayo Clin Proc 2006;81(6):758–67. DOI: 10.4065/81.6.758

9. Makatsariya A.D., Vorobyev A.V., Karapetyan L.G., Solopova A.G. Thrombophilia and problems of thrombosis prevention in cancer patients. Zhurnal akusherstva i zhenskikh bolezney = Journal of Obstetrics and Women’s Diseases 2012;61(6):3–17. (In Russ.)

10. Mandala M., Labianca R. Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management. Thrombosis Res 2010;125(Suppl 2):117–9.

11. Somonova O.V., Madzhuga A.V., Elizarova A.L. Thrombosis and thromboembolism in oncology. Gazeta Rossiyskogo obshchestva klinicheskoy onkologii = Newspaper of the Russian Society of Clinical Oncology 2015;(4):13–5. (In Russ.)

12. Sushinskaya T.V., Blinnikova L.A., Stuklov N.I. Assessment of the activity of the hemostasis system in patients with cervical cancer. Vestnik poslediplomnogo medicinskogo obrazovaniya = Bulletin of Postgraduate Medical Education 2016;(1):40–6. (In Russ.)

13. Komrokji R.S., Corrales-Yepez M., Kharfan-Dabaja M.A. et al. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol 2012;87(11):1006–9. DOI: 10.1002/ajh.23303

14. Bonfanti G., Bombelli L., Bozzetti F. et al. The role of CEA and liver function tests in the detection of hepatic metastases from colorectal cancer. HPB Surg 1990;3(1):29–36; discussion 36–7. DOI: 10.1155/1990/87874

15. Merrill A.Y., Garland M.M., Howard-McNatt M. et al. What is the utility of routine complete blood count, liver function tests, and chest X-ray in the evaluation of patients with clinically nodenegative breast cancer? Am Surg 2019;85(1):29–33.

16. Ramírez-Carmona W., Díaz-Fabregat B., Yuri Yoshigae A. et al. Are serum ferritin levels a reliable cancer biomarker? A systematic review and meta-analysis. Nutr Cancer 2022;74(6):1917–26. DOI: 10.1080/01635581.2021.1982996

17. Wang Q., Cui Q., Gao J.P., Xing R. Role of iron biomarkers and iron intakes in lung cancer risk: A systematic review and metaanalysis. J Trace Elem Med Biol 2022;74:127060. DOI: 10.1016/j.jtemb.2022.127060

18. Plays M., Müller S., Rodriguez R. Chemistry and biology of ferritin. Metallomics 2021;13(5):mfab021. DOI: 10.1093/mtomcs/mfab021

19. WHO Classification of Tumors of the Female Reproductive Organs. 4th edn. Eds.: R.J. Kurman, M.L. Carcangiu, C.S. Harrington. Geneva: WHO Press, 2014.

20. Arbyn M., Weiderpass E., Bruni L. et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health 2020;8(2):e191–203. DOI: 10.1016/S2214-109X(19)30482-6